PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2144548
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2144548
The clinical trial supplies market is projected to reach USD 8.95 billion by 2031, up from USD 5.60 billion in 2026, at a 9.8% CAGR from 2026 to 2031. The market is expected to grow as the number of clinical trials rises, pharmaceutical and biotechnology R&D spending expands, and sponsors conduct more global, multicenter, decentralized, and adaptive studies. These changes increase demand for compliant sourcing, packaging and labeling, storage, temperature-controlled distribution, and real-time supply visibility.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Services, Phase, Type, Therapeutic Area, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
However, high costs for comparator procurement, cold-chain handling, country-specific labeling, storage, and transportation can increase trial budgets. Drug shortages, geopolitical disruption, complex import requirements, and inaccurate demand forecasts may also delay deliveries and increase product wastage.

"Logistics & distribution services accounted for the largest share, by service, in 2024 and continued to lead in 2025."
Based on service, the clinical trial supplies market is segmented into sourcing & procurement; packaging & labeling; logistics & distribution; storage & retention; and other services, including biological sample management, destruction & waste management, and kit assembly. Logistics & distribution services held the largest share in 2025. This large share highlights the growing need to move investigational products, comparators, medical devices, and ancillary supplies across dispersed sites while maintaining chain of custody and product stability. Growth in biologics, vaccines, and cell & gene therapies is increasing demand for cold-chain, cryogenic, and ultra-low-temperature capabilities. Decentralized and direct-to-patient models further expand delivery destinations and require tighter coordination, monitoring, and returns management.
"The small molecules segment accounted for the largest share of the clinical trial supplies market, by type, in 2025."
Based on type, the global clinical trial supplies market is segmented into small molecules, biologics, and medical devices. Small molecules accounted for the largest share of market revenue in 2025, supported by established manufacturing processes, cost-efficient production, ease of oral administration, and broad use across oncology, cardiovascular, neurological, and infectious diseases. Biologics include monoclonal antibodies, vaccines, cell & gene therapies, recombinant proteins, plasma-derived products, biosimilars, and peptides. Many of these products require refrigerated, frozen, or cryogenic handling and continuous temperature monitoring. Medical-device trials add requirements for component control, study-specific labeling, device accountability, and controlled distribution. The resulting range of dosage forms, stability profiles, and handling requirements sustains demand for specialized clinical supply partners with global quality and logistics capabilities.
"Asia Pacific is expected to grow at the highest CAGR in the clinical trial supplies market during the forecast period."
The clinical trial supplies market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is estimated to record the highest CAGR during the forecast period, supported by expanding pharmaceutical and biopharmaceutical industries, competitive trial costs, favorable government policies, and a growing CRO base. The region is attracting more multinational trials, which increases demand for local depots, import and export support, country-specific labeling, comparator sourcing, and temperature-controlled delivery. North America accounted for the largest share of market revenue in 2025, supported by the adoption of decentralized trials and advanced cold-chain logistics. Europe also remains an important market because of its established clinical research infrastructure and substantial multinational study activity.
List of Companies Profiled in the Report
Research Coverage
This research report categorizes the clinical trial supplies market by service, phase, type, therapeutic area, end user, and region. Services covered include logistics & distribution, packaging, labeling & blinding, storage & retention, manufacturing, comparator sourcing, and other services. The report assesses Phase I, Phase II, Phase III, Phase IV, and bioavailability/bioequivalence studies; small molecules, biologics, and medical devices; and major therapeutic areas. End users include pharmaceutical & biotechnology companies, CROs & CDMOs, and other organizations such as medical-device companies and academic & research institutes. The scope includes detailed analysis of market drivers, restraints, opportunities, and challenges. It also evaluates leading providers through their business overview, service portfolio, partnerships, acquisitions, expansions, agreements, and other recent developments associated with the clinical trial supplies market. Competitive analysis covers established players and emerging companies across the market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall clinical trial supplies market and its subsegments. It will help stakeholders compare the competitive position and service capabilities of major providers and identify markets aligned with their expansion strategies. The report will also enable stakeholders to understand market demand across services, trial phases, therapy types, therapeutic areas, end users, and regions. It covers factors shaping growth, including clinical trial activity, supply-chain costs, decentralized trial models, digital supply technologies, drug shortages, and regulatory complexity.